Audited Supplier
QS-Pazopanib
635702-64-6
C21h23n7o2s.Clh
619-728-0
Metal
Normal
>12 Months
Pazopanib HCl
Pazopanib HCl Powder
White Powder
Pharmaceutical
White
99%
Pharmaceutical
99%
HPLC
C21h23n7o2s.Clh
473.972
1.2-1.4G/Cm3
>290°c
700°c
4.1
QS
Negotiable
Negotiable
Shaanxi Xi'an
Product Description
Pazopanib Hydrochloride Powder Multi-Target Pazopanib HCL
| Product Name | Pazopanib HCL |
| CASNO. | 635702-64-6 |
| Appearance | White Powder |
| MF | C21H23N7O2S.ClH |
| MW | 473.972 |
Pazopanib HCl is a multi-target tyrosine kinase inhibitor primarily used for the treatment of various cancers, including renal cell carcinoma, ovarian cancer, non-small cell lung cancer (NSCLC), and soft tissue sarcoma (STS)
Renal cell carcinoma: Pazopanib HCl is used as first-line treatment for advanced renal cell carcinoma patients, as well as for the treatment of advanced renal cell carcinoma patients who have received cytokine therapy. It can significantly prolong the survival of patients and alleviate disease-related symptoms.
Ovarian cancer: Pazopanib HCl exhibits certain activity in the treatment of platinum resistant or platinum refractory epithelial ovarian cancer, which can inhibit the growth and spread of tumor cells and improve the survival prognosis of patients
